Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up

Clinical Biochemistry

Volumn 33, Issue 2, 2000, Pages 115-123

  Vassilikos, Evyenia J K ^a   Yu, He ^b   Trachtenberg, John ^c   Nam, Robert K ^c   Narod, Steven A ^d   Bromberg, Irving L ^a,e   Diamandis, Eleftherios P ^e  

^a MOUNT SINAI HOSPITAL   (Canada)

^b Louisiana State University School of Medicine Shreveport   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer cure; Cancer monitoring; Cancer relapse; Prostate cancer; Prostate specific antigen; Tumor markers; Ultrasensitive assay

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASSAY; CANCER INVASION; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; TUMOR VOLUME;

AGED; DISEASE-FREE SURVIVAL; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033995859     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(99)00099-5     Document Type: Article

References (35)

1. Oesterling JE: Prostate-specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907.
2. McCormack R.T., Rittenhouse H.G., Finlay J.A., et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family A new era . Urology. 45:1995;729-744.
3. Diamandis E.P. Prostate specific antigen - its usefulness in clinical medicine. Trends Endocrinol Metab. 9:1998;310-316.
4. Stamey T.A., Kabalin J.N., McNeal J.E., et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 141:1989;1076.
5. Lightner D.J., Lange P.H., Reddy P.K., Moore L. Prostate-specific antigen and local recurrence after radical prostatectomy. J Urol. 144:1990;921.
6. Stein A., deKernion J.B., Smith R.B., et al. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol. 147:1992;942.
7. Frazier H.A., Robertson J.E., Humphrey P.A., Paulson D.F. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol. 149:1993;516.
8. Paulson D.F. Impact of radical prostatectomy in the management of clinically localized disease. J Urol. 152:1994;1826.
9. Diamandis E.P., Wong P.Y., et al. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 ug/L. J Urol. 157:1997;913-918.
10. Ellis W.J., Vessella R.L., Noteboom J.L., et al. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Urology. 50:1997;573.
11. Witherspoon L.R., Lapeyrolerie T. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol. 157:1997;1322-1328.
12. Klee G.G., Preissner C.M., Oesterling J.E. Development of a highly sensitive immunochemiluminometric assay for prostate-specific antigen. Urology. 44:1994;76-82.
13. Arai Y., Okubo K., Aodi Y., Maekawa S., et al. Ultrasensitive assay of prostate-specific antigen for early detection of residual cancer after radical prostatectomy. Int J Urol. 5:1998;550-555.
14. Haese A., Huland E., Graefen M., et al. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. J Urol. 16:1999;1206-1211.
15. Diamandis E.P., Yu H., Melegos D.N. Ultrasensitive prostate specific antigen assays and their clinical application. Clin Chem. 42:1996;853-857.
16. Yu H., Diamandis E.P. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem. 39:1993;2108-2114.
17. Ferguson R.A., Yu H., Kalyvas M., et al. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay potential applications in prostate and breast cancers . Clin Chem. 42:1996;675-684.
18. Christopoulos T.K., Diamandis E.P. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem. 64:1992;342-346.
19. Cox D.R. Regression models and life tables. J R Stat Soc B. 34:1972;187.
20. Schild S.E., Buskirk S.J., Wong W.W., et al. The use of radiotherapy for patients with isolated evaluation of serum prostate specific antigen following radical prostatectomy. J Urol. 156:1996;1725-1729.
21. Forman J.D., Meetze K., Pontes E., et al. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol. 158:1997;1439-1440.
22. Patel A., Dorey F., Franklin J., deKernion J.B. Recurrence patterns after radical retropubic prostatectomy clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen . J Urol. 158:1997;1441-1445.
23. Humphrey P.A., Fraizer H.A., Vollmer R.T., Paulson D.F. Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels. Cancer. 71:1993;1821.
24. Epstein J.I., Pizov G., Walsh P.C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 71:1993;3582.
25. Epstein J.I., Carmichael M., Partin A.W., Walsh P.C. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol. 149:1993;1478.
26. Trapasso J.G., deKernion J.B., Smith R.B., Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 152:1994;1821.
27. Catalona W.J., Smith D.S. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 152:1994;1837.
28. Ohori M., Goad J.R., Wheeler T.M., et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 152:1994;1843.
29. Zietman A.L., Edelstein R.A., Coen J.J., et al. Radical prostatectomy for adenocarcinoma of the prostate The influence of preoperative and pathologic findings on biochemical disease-free outcome . Urology. 43:1994;828.
30. Partin A.W., Piantadosi S., Sanda M.G., et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 45:1995;831.
31. Kupelian P., Katcher J., Levin H., et al. Correlation of clinical and pathological factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology. 48:1997;249.
32. Blute M.L., Bostwick D.G., Bergstralh E.J., et al. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology. 50:1997;733.
33. Tefilli M.V., Gheiler E.L., Tiguert R., et al. Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. J Urol. 160:1998;802.
34. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy. J Clin Oncol. 16:1998;3094.
35. Wheeler T.M., Dillioglugil O., Kattan M.W., et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol. 29:1998;856.